In particular, intranasal or dural application of TRPA1 agonists increases meningeal blood flow, neurogenic inflammation, nociceptive behaviors, intraganglionic transmission and release of a known target for migraine prevention and therapy, CGRP [15,20,21,22]. This evidence concerns the gene TRPA1 and migraine disorder.